Work

Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the phase II GEOMETRY mono-1 study.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.9056

Authors: Juergen Wolf, Edward B. Garon, Harry J.M. Groen, Daniel Shao-Weng Tan, Isabelle Gilloteau, Sylvie Le Mouhaer, Can Cai, Andrea Chassot-Agostinho, Maria Reynolds, Dawn Odom, Rebecca Suk Heist

Institutions: University of Cologne, University Hospital Cologne, University of California, Los Angeles, University Medical Center Groningen, National Cancer Centre Singapore, Novartis (France), RTI Health Solutions, Massachusetts General Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Novartis

OpenAlex ID: W3171625467

Cites:

Cited by:

Related to: 10